首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   75篇
  免费   2篇
电工技术   3篇
化学工业   2篇
能源动力   3篇
轻工业   2篇
水利工程   1篇
无线电   9篇
一般工业技术   14篇
冶金工业   33篇
原子能技术   5篇
自动化技术   5篇
  2023年   3篇
  2022年   1篇
  2021年   2篇
  2020年   4篇
  2019年   7篇
  2017年   2篇
  2016年   1篇
  2015年   1篇
  2014年   1篇
  2013年   1篇
  2012年   1篇
  2011年   3篇
  2010年   1篇
  2009年   1篇
  2008年   2篇
  2006年   1篇
  2005年   1篇
  2004年   1篇
  2000年   1篇
  1998年   1篇
  1996年   3篇
  1995年   8篇
  1994年   5篇
  1993年   2篇
  1992年   1篇
  1991年   7篇
  1990年   3篇
  1989年   1篇
  1987年   4篇
  1986年   2篇
  1985年   2篇
  1983年   1篇
  1979年   1篇
  1976年   1篇
排序方式: 共有77条查询结果,搜索用时 15 毫秒
1.
2.
Poly(3,4-ethylenedioxythiophene):polystyrene sulfonate (PEDOT:PSS) has been one of the most established hole transport layers (HTL) in organic solar cells (OSCs) for several decades. However, the presence of PSS ions is known to deteriorate device performance via a number of mechanisms including diffusion to the HTL-active layer interface and unwanted local chemical reactions. In this study, it is shown that PSS ions can also result in local p-doping in the high efficiency donor:non-fullerene acceptor blends – resulting in photocurrent loss. To address these issues, a facile and effective approach is reported to improve the OSC performance through a two-component hole transport layer (HTL) consisting of a self-assembled monolayer of 2PACz ([2-(9H-Carbazol-9-yl)ethyl]phosphonic acid) and PEDOT:PSS. The power conversion efficiency (PCE) of 17.1% using devices with PEDOT:PSS HTL improved to 17.7% when the PEDOT:PSS/2PACz two-component HTL is used. The improved performance is attributed to the overlaid 2PACz layer preventing the formation of an intermixed p-doped PSS ion rich region (≈5–10 nm) at the bulk heterojunction-HTL contact interface, resulting in decreased recombination losses and improved stability. Moreover, the 2PACz monolayer is also found to reduce electrical shunts that ultimately yield improved performance in large area devices with PCE enhanced from 12.3% to 13.3% in 1 cm2 cells.  相似文献   
3.
Rapid growth of digital data and their security concerns increases the significance of enhancing advanced encryption techniques. Encryption is the backbone of secure communication in networks and the physical process of scrambling and permuting data in order to make them impossible to understand for unauthorized users. This paper proposes a novel audio signal encryption method, based on a mixture of three chaos functions. Due to the reversibility of the chaos functions, the decryption process is the inverse of the encryption process. This method was applied to audio signals with various sizes and the encoded messages were compared to the original ones. Simulation results and theoretical analyses show that the proposed approach offers a significant gain in terms of robustness and computational complexity.  相似文献   
4.
Higher concentration of protons in the mitochondrial intermembrane space compared to the matrix results in an electrochemical potential causing the back flux of protons to the matrix. This proton transport can take place through ATP synthase complex (leading to formation of ATP) or can occur via proton transporters of the mitochondrial carrier superfamily and/or membrane lipids. Some mitochondrial proton transporters, such as uncoupling proteins (UCPs), transport protons as their general regulating function; while others are symporters or antiporters, which use the proton gradient as a driving force to co-transport other substrates across the mitochondrial inner membrane (such as phosphate carrier, a symporter; or aspartate/glutamate transporter, an antiporter). Passage (or leakage) of protons across the inner membrane to matrix from any route other than ATP synthase negatively impacts ATP synthesis. The focus of this review is on regulated proton transport by UCPs. Recent findings on the structure and function of UCPs, and the related research methodologies, are also critically reviewed. Due to structural similarity of members of the mitochondrial carrier superfamily, several of the known structural features are potentially expandable to all members. Overall, this report provides a brief, yet comprehensive, overview of the current knowledge in the field.  相似文献   
5.
6.
A technique for finding transmitter and receiver filters for a wide class of digital communication systems which minimize the bit-error rate (BER) is presented. The technique uses Monte Carlo simulation to estimate the BER and mean field annealing (MFA) to optimize the pulse shapes. Modeling of the link can be as complex as simulation will allow, while MFA is resistant to the statistical variation in the BER estimate from the simulation. Initially, the MFA technique was applied to a binary symmetric channel in a nonsimulation environment, and an approximate analysis of the behavior of MFA for this problem was performed. In a more complex example, MFA was coupled with Monte Carlo simulation techniques to find near-optimal transmit and receive filters for a satellite communications link, taking 6 CPU hours on a DECstation 3100. The BER of the link was found to be as much as three orders of magnitude lower when using the MFA-constructed optimal filters than when using filters from other comparison results. For this example, the pulse shapes obtained using MFA exhibit a low BER even as the parameter controlling the nonlinearity of the satellite-link model is varied over a wide range, thus showing the solution is robust  相似文献   
7.
5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer. Research has focused on the biomodulation of 5-FU in order to attempt to improve the cytotoxity and therapeutic effectiveness of this drug in the treatment of advanced colorectal cancer. Modulation of 5-FU by methotrexate (MTX), trimetrexate (TMTX), interferon-alpha (IFN-alpha), leucovorin (LV), or N-(phosphonacetyl)-L-asparte acid (PALA) has produced higher response rates than those observed with 5-FU alone. Methotrexate may improve the durability of response to or survival with 5-FU, but with inferior results compared with those in trials of 5-FU and leucovorin. Trimetrexate produces a number of responses, and further phase III trials are in progress to confirm the results of promising phase II trials with this drug. IFN-alpha has shown therapeutic efficiency when combined with 5-FU alone or with 5-FU and leucovorin, but latest studies with these combinations have shown increased toxicity. Initial single-institution phase I trials with 5-FU and PALA reported promising responses, but the latter responses with PALA were not substantiated in randomized multicenter trials. Leucovorin enhances the cytotoxic activity of 5-FU in vitro and in vivo, and several clinical trials have shown improved response rates and possible trends in improved survival when such therapy is compared with the use of 5-FU as a single-agent. More recent randomized trials have focused their attention on determining the optimal dose and schedule with this combination for producing a better clinical response with minimal toxicity. Schedules using infusional 5-FU appear to be the most active regimens when 5-FU is used as a single agent, as demonstrated by recent randomized trials. The Southwest Oncology Group (SWOG) and the Eastern Cooperative Oncology Group (ECOG) have performed separate randomized trials and have shown that the optimal regimens employ infusional 5-FU as a single agent, and that these are the least toxic regimens, perhaps more effective, and associated with a better quality of life. Future studies will focus on infusional regimens involving either short-term, high-dose protracted or long-term, low-dose protracted infusion of 5-FU, since these regimens have shown the most favorable toxicity spectrum and produced the longest survival times. Future research will also focus on the evaluation of various methods of delivery of 5-FU, including oral administration of the drug in combination with compounds that can modify its catabolism.  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号